ATE448003T1 - Verwendung von substituierten 1,2,3-indolizin- derivaten zur behandlung von krankheiten im zusammenhang mit einer pathologischen angiogenese - Google Patents

Verwendung von substituierten 1,2,3-indolizin- derivaten zur behandlung von krankheiten im zusammenhang mit einer pathologischen angiogenese

Info

Publication number
ATE448003T1
ATE448003T1 AT05717556T AT05717556T ATE448003T1 AT E448003 T1 ATE448003 T1 AT E448003T1 AT 05717556 T AT05717556 T AT 05717556T AT 05717556 T AT05717556 T AT 05717556T AT E448003 T1 ATE448003 T1 AT E448003T1
Authority
AT
Austria
Prior art keywords
alk
alkyl
alkoxy
coor
carboxy
Prior art date
Application number
AT05717556T
Other languages
English (en)
Inventor
Alain Badorc
Francoise Bono
Marie-Francoise Bordes
Jean-Michel Foidart
Nathalie Guillo
Agnes Noel
Jean-Marie Rakic
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE448003T1 publication Critical patent/ATE448003T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
AT05717556T 2004-02-05 2005-02-04 Verwendung von substituierten 1,2,3-indolizin- derivaten zur behandlung von krankheiten im zusammenhang mit einer pathologischen angiogenese ATE448003T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0401094A FR2865934B1 (fr) 2004-02-05 2004-02-05 Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
PCT/FR2005/000253 WO2005082457A2 (fr) 2004-02-05 2005-02-04 Utilisation de derives d’indolizine 1,2,3 substitues pour le traitement de maladies liees à une angiogenese pathologique choroïdienne.

Publications (1)

Publication Number Publication Date
ATE448003T1 true ATE448003T1 (de) 2009-11-15

Family

ID=34778525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05717556T ATE448003T1 (de) 2004-02-05 2005-02-04 Verwendung von substituierten 1,2,3-indolizin- derivaten zur behandlung von krankheiten im zusammenhang mit einer pathologischen angiogenese

Country Status (20)

Country Link
US (1) US8034828B2 (de)
EP (1) EP1713543B1 (de)
JP (1) JP5268258B2 (de)
KR (1) KR101199730B1 (de)
CN (1) CN1917922B (de)
AT (1) ATE448003T1 (de)
AU (1) AU2005216671B2 (de)
BR (1) BRPI0507509A (de)
CA (1) CA2553895C (de)
CY (1) CY1109669T1 (de)
DE (1) DE602005017581D1 (de)
DK (1) DK1713543T3 (de)
ES (1) ES2335900T3 (de)
FR (1) FR2865934B1 (de)
HR (1) HRP20100030T1 (de)
IL (1) IL177088A (de)
PL (1) PL1713543T3 (de)
PT (1) PT1713543E (de)
SI (1) SI1713543T1 (de)
WO (1) WO2005082457A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP2270043A1 (de) * 2009-07-03 2011-01-05 Sanofi-Aventis Extrazelluläre allosterische Inhibitorbindungsdomäne aus einem Tyrosinkinaserezeptor
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf

Also Published As

Publication number Publication date
CY1109669T1 (el) 2014-08-13
HRP20100030T1 (hr) 2010-03-31
DK1713543T3 (da) 2010-03-22
FR2865934B1 (fr) 2006-05-05
FR2865934A1 (fr) 2005-08-12
KR20070034986A (ko) 2007-03-29
EP1713543A2 (de) 2006-10-25
WO2005082457A3 (fr) 2005-11-10
AU2005216671A1 (en) 2005-09-09
HK1101065A1 (en) 2007-10-05
DE602005017581D1 (de) 2009-12-24
KR101199730B1 (ko) 2012-11-08
CA2553895A1 (fr) 2005-09-09
EP1713543B1 (de) 2009-11-11
PT1713543E (pt) 2009-12-15
US8034828B2 (en) 2011-10-11
JP5268258B2 (ja) 2013-08-21
SI1713543T1 (sl) 2010-03-31
IL177088A0 (en) 2006-12-10
CN1917922B (zh) 2013-06-12
PL1713543T3 (pl) 2010-04-30
ES2335900T3 (es) 2010-04-06
JP2007520534A (ja) 2007-07-26
AU2005216671B2 (en) 2010-09-16
WO2005082457A2 (fr) 2005-09-09
CA2553895C (fr) 2013-04-02
IL177088A (en) 2010-12-30
CN1917922A (zh) 2007-02-21
BRPI0507509A (pt) 2007-06-26
US20090030034A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
BRPI0513750A (pt) 2-fenilamino-benzamidas-5-substituìdas como inibidoras de mek
CY1109669T1 (el) Χρηση υποκατεστημενων παραγωγων της ινδολιζινης 1,2,3 για τη θεραπεια νοσων που σχετιζονται με μια παθολογικη χοριοειδη αγγειογενεση
MX2023013080A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
PE20030581A1 (es) Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo
ATE337785T1 (de) Tiotropiumsalze zur behandlung von entzündlichen erkrankungen
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
RU2002124873A (ru) Глюкопиранозилоксибензилбензольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для получения указанных производных
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
ATE357453T1 (de) Comt-inhibitoren
DE602005011452D1 (de) Zur behandlung von entzündungen geeignete indole
CY1109546T1 (el) Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
DE60130030D1 (de) Verfahren zur behandlung von glaukom
DE69930621D1 (de) Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
RU2009138028A (ru) Новое профилактическое и/или лекарственное средство против невропатической боли
ATE352317T1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE60310975D1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
WO2008099853A1 (ja) 歯周組織再生促進用医薬組成物及び歯周組織再生促進剤

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1713543

Country of ref document: EP